Alvotech Completes $137 Million Private Share Placement REYKJAVIK, ICELAND (

Alvotech Completes $137 Million Private Share Placement

REYKJAVIK, ICELAND (January 23, 2023) Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture

of biosimilar medicines for patients worldwide, today announced the completion of a private placement of approximately $137 million, at current exchange rates, of its ordinary shares, par value $0.01 per share, (the Shares ) at a

purchase price of $11.57 per Share at current exchange rates. The Shares are expected be delivered from previously issued treasury shares held by Alvotech s subsidiary, Alvotech Manco ehf.

The offer or sale of the Shares was made in an overseas directed offering directed solely into Iceland to professional clients or eligible counterparties in

accordance with European Parliament and Council Directive 2014/65/EC, and in accordance with local laws and customary practices and documentation.

Private Placement was initiated on January 19, 2023 and completed on January 22, 2023. Closing and settlement is expected on February 10, 2023, subject to customary closing conditions. Alvotech intends to use the net proceeds from the

private placement offering for general corporate purposes.

This communication is being issued pursuant to and in accordance with Rule 135c under the U.S.

Securities Act, is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States or elsewhere, nor shall there be any sale of any such securities in any state or

jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. The Shares have not been, and will not be, registered under the United States

Securities Act, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Alvotech is a biotech company, founded by

Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled

by a fully integrated approach and broad in-house capabilities. Alvotech s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis,

respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and

large parts of South America, Africa and the Middle East. Alvotech s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan),

Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India,

Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and

South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made

available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

Forward Looking Statements

Certain statements in this communication may be considered forward-looking statements within the meaning of the Private Securities Litigation

Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech s expectations regarding its expected future business,

financial performance, the satisfaction of the closing conditions, the closing date of the private placement offering, the use of proceeds from the private placement offering, and the settlement mechanics, including the origin of the Shares to be

delivered upon Closing. In some cases, you can identify forward-looking statements by terminology such as may , should , expect , intend , will , estimate , anticipate ,

believe , predict , potential , aim or continue , or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks,

uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while

considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech s control. Factors that may cause actual results to differ

materially from current expectations include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against Alvotech or others following the business combination between Alvotech Holdings S.A., Oaktree

Acquisition Corp. II and Alvotech; (2) changes in applicable laws or regulations; (3) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (4) Alvotech s estimates of

expenses and profitability; (5) Alvotech s ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (6) actions of regulatory authorities, which may affect the initiation, timing and

progress of clinical studies or future regulatory approvals or marketing authorizations; (7) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (8) the ability of

Alvotech s partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (9) Alvotech s ability to obtain and maintain regulatory approval or

authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (10) the success of Alvotech s current and future collaborations, joint ventures, partnerships or licensing

arrangements; (11) Alvotech s ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (12) Alvotech s ability to manufacture sufficient commercial supply of its approved

products; (13) the outcome of ongoing and future litigation regarding Alvotech s products and product candidates; (14) the potential impact of the ongoing COVID-19 pandemic on the FDA s

review timelines, including its ability to complete timely inspection of manufacturing sites; (15) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, war in Ukraine and

global geopolitical tension, and the ongoing and evolving COVID-19 pandemic on the Alvotech s business, financial position, strategy and anticipated milestones; and (16) other risks and uncertainties

set forth in the sections entitled Risk Factors and Cautionary Note Regarding Forward-Looking Statements in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that

Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a

representation by any person that the

forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on

forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may

affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this

communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any

respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication.

Alvotech Investor Relations and Global

alvotech.ir[at]alvotech.com